Amgen’s Amjevita became the first U.S. Humira biosimilar on January 31, 2023. Within twelve months, eleven additional adalimumab biosimilars had […]

The U.S. generic drug market generates roughly $120 billion in annual revenue and absorbs more than 90% of all dispensed

The traditional patent bargain—a 20-year monopoly in exchange for public disclosure—has transitioned into a sophisticated system of legal layering. In

How to attack weak patents, fortify your portfolio, and turn every validity challenge into a competitive lever — across the

The moment a brand-name pharmaceutical company files a patent, a clock starts. Somewhere else in the world—often in Ahmedabad, Mumbai,

A deep-dive reference for pharma IP strategists, ANDA portfolio managers, formulation leads, and institutional investors tracking the generic drug sector.

How to diagnose the six most common grounds for pharmaceutical patent rejection — and the prosecution strategies that actually reverse

A deep-dive resource covering discovery frameworks, platform architectures, IP valuation, clinical case studies, ROI modeling, regulatory strategy, and the next

Part I: The Failing Commercial Architecture The commercial model that generated decades of reliable profit for large-cap pharmaceutical companies was